PINE BROOK, N.J.
, Nov. 30
2010 /PRNewswire/ -- Alberto Gonzalez Garcia
, M.D. has joined Diopsys, Inc. as its new Research Director. Dr. Gonzalez will head all scientific research for new product development and enhancement projects, including clinical studies. His extensive experience in neuro-ophthalmology and glaucoma research will give the Diopsys scientific and engineering teams a valuable resource for developing the most advanced, patient-friendly vision testing equipment available.
"I've been involved in medical research since the beginning of my career, and one of my main interests is how technology can move medicine forward to help as many people as possible," Dr. Gonzalez says. "I'm excited to bring both my passions research and technology to help Diopsys advance the science of vision testing."
Dr. Gonzalez received his medical training at Finlay-Albarran in Havana, Cuba. He completed fellowships in Neuro-Ophthalmology at the National Institute of Neurology and Neurosurgery in Cuba, and in Glaucoma at the Hamilton Glaucoma Center at the University of California San Diego. He was Chief of the Neuro-Ophthalmology Department at the National Institute of Neurology and Neurosurgery and a clinician and surgeon at the National Institute of Ophthalmology in Cuba. He has published and contributed to numerous books and studies in the areas of early diagnosis of glaucoma, ischemic optic neuropathy, and optic coherence tomography (OCT) in the diagnosis of retina and optic nerve diseases, among many others.
Joe Fontanetta, President and CEO of Diopsys says, "We are extremely pleased to have Dr. Gonzalez join us as Research Director. He brings with him a wealth of ophthalmic knowledge, as well as a strong technical background. He is now working on new software that improves the sensitivity of current OCT technology that will allow doctors to more accurately diagnose diseases such as glaucoma using their existing OCT images."
Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care. The company specializes in the development and marketing of patient-friendly, non-invasive diagnostic vision testing equipment utilizing Evoked Potential technology. Diopsys has developed and markets the patented Enfant® Pediatric VEP Vision Testing System, a device used by pediatricians in testing for visual deficits, including amblyopia, in children as young as six months of age. Diopsys also developed and markets the Diopsys® NOVA-DT (Diagnostic & Tracking), Diopsys® NOVA-TR (Transient Response) and Diopsys® NOVA-DN (Diseases of the Optic Nerve) VEP Vision Testing Systems utilized by ophthalmologists and optometrists for the detection, diagnosis and treatment of vision disorders.
SOURCE Diopsys, Inc.